Brief communication: immunogenicity of measles vaccine when co-administered with 10-valent pneumococcal conjugate vaccine

ZQ Toh; B Temple; TN Huu; VTT Dai; NT Toan; DY Uyen; K Bright; LAH Do; EK Mulholland; PV Licciardi

Journal article

Brief communication: immunogenicity of measles vaccine when co-administered with 10-valent pneumococcal conjugate vaccine

ZQ Toh, B Temple, TN Huu, VTT Dai, NT Toan, DY Uyen, K Bright, LAH Do, EK Mulholland, PV Licciardi

Npj Vaccines | NATURE RESEARCH | Published : 2020

DOI: 10.1038/s41541-020-00225-z

Download PDF

Abstract

This brief communication describes the findings from a randomised controlled trial in Vietnam that co-administration of measles vaccine (MV) with 10-valent pneumococcal conjugate vaccine (PCV10, Synflorix®, GSK) does not affect the immunogenicity of MV. These findings are most relevant for low- and middle-income countries (LMICs) in Asia considering PCV introduction.

University of Melbourne Researchers

Zheng Toh Author

Anna Do Author

Paul Licciardi Author

Related Projects (1)

Evaluation of simplified childhood vaccination schedules incorporating pneumococcal vaccines

This project aims to come up with a vaccination schedule to make pneumococcal vaccines more effective and affordable for Fiji and other deve..

Grants

Awarded by Bill and Melinda Gates Foundation

Funding Acknowledgements

We thank the study participants and their families. We also thank Laboratory Services at the Royal Children's Hospital, Parkville, Australia for performing the measles immunogenicity testing. This work was supported by the National Health and Medical Research Council of Australia (grant number 566792) and the Bill & Melinda Gates Foundation (grant number OPP1116833). GlaxoSmithKline Biologicals SA donated the doses of PCV10.